Enliven Therapeutics insider to sell 75,000 shares

Enliven Therapeutics insider plans to sell additional shares under Rule 144.

Rhea-AI Filing Summary

Enliven Therapeutics insider plans to sell additional shares under Rule 144. A notice has been filed to sell 75,000 shares of Enliven Therapeutics common stock through Jefferies LLC on Nasdaq, with an aggregate market value of $1,743,750 and 59,000,000 shares outstanding. The shares to be sold are founder shares originally acquired on September 1, 2019 from Enliven Therapeutics.

The filing also lists prior sales over the past three months by the same seller, including 12,500 Enliven Therapeutics securities sold on November 17, 2025 for $272,739.30 and 38,757 sold on January 8, 2026 for $930,261.95, plus an additional 43,743 sold on January 9, 2026 for $1,089,200.70.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Enliven Therapeutics (ELVN) Form 144 filing disclose?

It discloses a planned sale of 75,000 shares of Enliven Therapeutics common stock under Rule 144, to be executed through Jefferies LLC on Nasdaq.

How many Enliven Therapeutics shares are planned to be sold and at what value?

The notice covers 75,000 common shares with an aggregate market value of $1,743,750, based on the figures in the filing.

Who is selling the Enliven Therapeutics (ELVN) shares in this Form 144?

The securities are being sold for the account of Samuel Kintz, who holds founder shares originally acquired from Enliven Therapeutics on September 1, 2019.

Which broker and exchange are involved in the planned ELVN share sale?

The planned sale will be handled by Jefferies LLC, with the shares to be sold on Nasdaq, as stated in the filing.

What prior Enliven Therapeutics share sales are reported in the last 3 months?

Reported past 3‑month sales include 12,500 securities on November 17, 2025 for $272,739.30, 12,500 on October 17, 2025 for $266,653.75, 5,000 on December 17, 2025 for $81,892.60, 38,757 on January 8, 2026 for $930,261.95, and 43,743 on January 9, 2026 for $1,089,200.70.

How many Enliven Therapeutics shares are outstanding according to the Form 144?

The filing states that 59,000,000 shares of Enliven Therapeutics common stock are outstanding.

What type of shares are being sold in the Enliven Therapeutics Form 144?

The filing identifies the securities as common stock and specifies that the 75,000 shares to be sold are founder shares acquired on September 1, 2019.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 04:49 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001967168
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Kintz Samuel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	75000	1743750.00	59000000	01/09/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder Shares	Enliven Therapeutics			75000	09/01/2019	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	11/17/2025	12500	272739.30
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	10/17/2025	12500	266653.75
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	12/17/2025	5000	81892.60
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	01/08/2026	38757	930261.95
Samuel Kintz 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	01/09/2026	43743	1089200.70

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 11/15/2024, and all representations regarding material non-public information were made as of the adoption of the plan. The shares in this filing will be sold from THE KINTZ & EGAN TRUST UAD 03/30/19.
Date of Notice	01/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/15/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Samuel Kintz
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)